· Updated · Venture Capital Tracker · investment-strategies · 3 min read
Expedition Therapeutics’ $115M Series B: General Atlantic Bets on COPD DPP1
General Atlantic led Expedition’s oversubscribed $115M Series B as the biotech dosed the first patient in a global Phase 2 COPD trial of EXPD-101 — a China-sourced NewCo twist.
VCT data record
Funding event facts
Source-backed financing and transaction details. Unknown terms remain undisclosed rather than estimated.
Expedition Therapeutics raises $115M Series B
- Event type
- Funding Round
- Event date
- Aug 5, 2026
- Stage / label
- Series B
- Amount
- $115M
- Confidence
- Company Disclosed
Company / target: Expedition Therapeutics
Lead: General Atlantic
Participants: RA Capital , Vivo Capital , Sofinnova Investments , Novo Holdings , Forbion , Dawn Biopharma , Adage Capital , Balyasny Asset Management , Logos Capital , Sanofi Ventures , BVF Partners , Venrock Healthcare Capital Partners
Sources: expeditiontx.com
Expedition Therapeutics closed an oversubscribed $115 million Series B on August 5, 2026, led by General Atlantic, with RA Capital, Vivo Capital, and a deep returning life-sciences syndicate. The same day, Expedition said the first patient was dosed in a global Phase 2 COPD trial of EXPD-101, a next-generation DPP1 inhibitor. Earlier August VCT roundups flagged this deal as a coverage gap — this is the deep dive.
Key facts
| Field | Detail |
|---|---|
| Company | Expedition Therapeutics (San Francisco) |
| Round | $115M Series B (oversubscribed) |
| Date | August 5, 2026 |
| Lead | General Atlantic (Brett Zbar joins board) |
| Key participants | RA Capital, Vivo Capital + full existing syndicate |
| Lead asset | EXPD-101 — oral once-daily DPP1 inhibitor for COPD |
| Clinical status | First patient dosed, global randomized Phase 2 |
| Structure note | Asset in-licensed from Fosun Pharma (China NewCo pattern) |
| Prior | ~$165M Series A disclosed Oct 2025 (Endpoints) |
Who uses the product — and for what job
Near-term users: clinical investigators and COPD trial participants across North/South America, Europe, and Asia (~600-patient Phase 2 described in Endpoints coverage; primary completion listed toward summer 2028 on public registries).
Eventual users (if approved): patients and pulmonologists treating COPD where neutrophilic inflammation drives exacerbations — a mechanism current symptom-management therapies do not fully address, per company and investigator commentary.
Job today: generate Phase 2 evidence that selective DPP1 inhibition improves outcomes enough to justify Phase 3 capital. Expedition claims first-mover status on a global randomized Phase 2 DPP1 COPD trial.
Why now
- COPD remains a top global killer; standard of care still leaves inflammatory progression under-treated.
- DPP1 (dipeptidyl peptidase 1) sits upstream of neutrophil serine proteases — a mechanistic bet biotech capital understands how to price at Phase 2.
- China-sourced assets + Western clinical development (NewCo) have become a repeatable financing pattern; Expedition is one of ~19 such NewCos Endpoints tracked since early 2025.
- Phase 1 claimed clean enough PK/safety for once-daily oral dosing — the classic Series B trigger for a clinical biotech.
Why General Atlantic — portfolio fit
General Atlantic manages ~$129B AUM (as of Jun 30, 2026, per its Expedition release) across growth equity and adjacent strategies. Life sciences under Zbar buys inflection assets with global development plans — not seed discovery platforms.
Likely founder rationale: a lead that can write a nine-figure clinical check, put a life-sciences MD on the board, and sit comfortably next to RA Capital / Novo / Forbion / Sanofi Ventures — the syndicate already fluent in NewCo COPD risk.
| Dimension | Fit |
|---|---|
| Stage | Phase 2 clinical financing |
| Thesis | Differentiated respiratory/inflammation asset |
| Geography | U.S. NewCo + global trial footprint |
| Structure | China in-license + Western development |
We do not currently list General Atlantic as a /fund/ page — investor names are primary-sourced from company/GA materials.
Competitive map
| Player / path | Lane |
|---|---|
| Existing COPD SoC (LABA/LAMA/ICS, biologics subsets) | Symptom / phenotype management; different MoA |
| Other DPP1 / neutrophil-pathway programs | Same biology race; Expedition claims global Ph2 first |
| Broader anti-inflammatory pipelines | Crowded; differentiation is oral DPP1 + COPD focus |
| Pure China domestic developers | Different regulatory/commercial path |
Market signal
$115M oversubscribed at first-patient-in is the biotech market paying for a clear clinical plan, not an AI slogan. Absence of a disclosed valuation means you should underwrite dilution and Phase 2 risk — not invent a post-money for memos.
When not to use this as a template
- Wrong if you treat NewCo in-licensing as “de-risked” — IP, CMC, and cross-border diligence still bite.
- Wrong if Phase 1 tolerability is equated with Phase 2 efficacy.
- Wrong if you compare this round to SaaS ARR multiples.
Practical takeaway
- Founders (biotech): Time the raise to a real clinical milestone (FPI), then stack a specialist lead + crossover life-sciences book.
- Investors: Underwrite neutrophil COPD biology and China-license terms as carefully as enrollment speed.
- Operators / scouts: Watch Phase 2 endpoints and exacerbation rates — that is the binary, not the press release.
Sources
- Expedition Therapeutics (Aug 5, 2026): https://expeditiontx.com/news/expedition-therapeutics-announces-oversubscribed-115-million-series-b-financing-to-advance-next-generation-dpp1-inhibitor-for-copd/
- General Atlantic media page: https://www.generalatlantic.com/media-article/expedition-therapeutics-announces-oversubscribed-115-million-series-b-financing-to-advance-next-generation-dpp1-inhibitor-for-copd/
- Endpoints News (NewCo context): https://endpoints.news/expedition-gets-another-115m-for-its-twist-on-china-newco-model/
- Related: /2026-august-9-10-investment-news-chips-infra-biotech
Follow Venture Capital Tracker in Google
Add VCT as a preferred source to make our venture-capital coverage easier to find in Google Search.
Last updated:
Editorial note: AI tools assisted with research, structure, or drafting. Venture Capital Tracker retains human editorial responsibility for factual accuracy, relevance, and source quality before publication.
